Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002425 · ClinicalTrials.gov registry record · Phase 4
The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT00002425: Completed Phase 4 study, sponsored by Hoffmann-La Roche.
NCT00002425 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 400 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002425, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
To evaluate the safety and antiretroviral activity of saquinavir soft gelatin capsule formulation (SQV-SGC) in combination with other antiretroviral drugs.
Interventions
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Phase | Phase 4 |
What the finished NCT00002425 record still lists
NCT00002425 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 1 intervention - of which Saquinavir is the first listed.
NCT00002425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002425 about?
NCT00002425 is a clinical study titled "The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs". To evaluate the safety and antiretroviral activity of saquinavir soft gelatin capsule formulation (SQV-SGC) in combination with other antiretroviral drugs.
What is the current status of trial NCT00002425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants.
What interventions are being tested in trial NCT00002425?
The interventions under investigation include: Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002425?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002425's enrollment target sits among peer trials
400 211th of 2000 higher than 1,784 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository